Ken Griffin Biotechnology

Citadel Advisors LLC

  • $559 Billion
  • Q4 2024

Stock List

Stock Option Type Value Options Held Last Trade Trade History
BCRX
Biocryst Pharmaceuticals Inc
CALL
$941,000
125K
Q4 2024
Reduced 7.38%
MLTX
Moon Lake Immunotherapeutics
PUT
$940,000
17.7K
Q4 2024
Reduced 5.86%
LEGN
Legend Biotech Corp
PUT
$914,000
28.1K
Q4 2024
Added 120.64%
ARWR
Arrowhead Pharmaceuticals, Inc.
CALL
$913,000
48.6K
Q4 2024
Reduced 68.75%
MIRM
Mirum Pharmaceuticals, Inc.
PUT
$905,000
21.9K
Q4 2024
Added 8.61%
GERN
Geron Corp
CALL
$894,000
253K
Q4 2024
Reduced 10.68%
MNKD
Mannkind Corp
CALL
$884,000
138K
Q4 2024
Reduced 54.67%
CAPR
Capricor Therapeutics, Inc.
CALL
$883,000
63.8K
Q4 2024
New holding
SAVA
Cassava Sciences Inc
CALL
$878,000
372K
Q2 2024
Added 763.25%
ARCT
Arcturus Therapeutics Holdings Inc.
PUT
$875,000
51.6K
Q4 2024
Reduced 81.97%
WVE
Wave Life Sciences Ltd.
CALL
$856,000
69.2K
Q4 2024
Reduced 99.66%
KYMR
Kymera Therapeutics, Inc.
CALL
$852,000
21.2K
Q4 2024
Reduced 4.51%
OCUL
Ocular Therapeutix, Inc
PUT
$851,000
99.7K
Q4 2024
Added 4.62%
ARQT
Arcutis Biotherapeutics, Inc.
CALL
$841,000
60.4K
Q4 2024
Reduced 97.06%
CRVS
Corvus Pharmaceuticals, Inc.
PUT
$838,000
161K
Q4 2024
Reduced 18.91%
VRDN
Viridian Therapeutics, Inc.\De
CALL
$828,000
43.2K
Q4 2024
Added 48.53%
QSI
Quantum Si Inc
PUT
$797,000
295K
Q3 2024
Reduced 64.76%
RNA
Avidity Biosciences, Inc.
PUT
$788,000
27.1K
Q4 2024
New holding
IDYA
Ideaya Biosciences, Inc.
CALL
$788,000
30.7K
Q4 2024
Added 74.54%
OMER
Omeros Corp
CALL
$786,000
79.6K
Q4 2024
Added 45.32%
PTCT
Ptc Therapeutics, Inc.
CALL
$762,000
16.9K
Q4 2024
Added 91.53%
SAVA
Cassava Sciences Inc
PUT
$752,000
319K
Q2 2024
Added 763.25%
PHAT
Phathom Pharmaceuticals, Inc.
PUT
$725,000
89.4K
Q4 2024
Reduced 67.33%
RVNC
Revance Therapeutics, Inc.
CALL
$722,000
281K
Q4 2024
New holding
HRMY
Harmony Biosciences Holdings, Inc.
PUT
$719,000
20.9K
Q4 2024
Added 784.58%
WVE
Wave Life Sciences Ltd.
PUT
$718,000
58.1K
Q4 2024
Reduced 99.66%
MRUS
Merus N.V.
PUT
$714,000
17K
Q4 2024
Reduced 96.3%
CRVS
Corvus Pharmaceuticals, Inc.
CALL
$712,000
137K
Q4 2024
Reduced 18.91%
GALT
Galectin Therapeutics Inc
CALL
$688,000
579K
Q2 2024
Reduced 96.64%
TARS
Tarsus Pharmaceuticals, Inc.
CALL
$686,000
12.4K
Q4 2024
Reduced 79.36%
CLDX
Celldex Therapeutics, Inc.
PUT
$677,000
26.8K
Q4 2024
Reduced 16.43%
SAGE
Sage Therapeutics, Inc.
CALL
$659,000
122K
Q4 2024
Reduced 86.16%
HUMA
Humacyte, Inc.
CALL
$635,000
126K
Q4 2024
Added 11.96%
EYPT
Eye Point Pharmaceuticals, Inc.
CALL
$627,000
84.2K
Q4 2024
Added 75.28%
ETNB
89bio, Inc.
PUT
$625,000
81.6K
Q4 2024
Added 85.0%
IBRX
Immunity Bio, Inc.
CALL
$624,000
244K
Q4 2024
Reduced 77.3%
SGMO
Sangamo Therapeutics, Inc
PUT
$620,000
608K
Q4 2024
Added 10.63%
IDYA
Ideaya Biosciences, Inc.
PUT
$619,000
24.1K
Q4 2024
Added 74.54%
URGN
Uro Gen Pharma Ltd.
CALL
$614,000
57.7K
Q4 2024
Reduced 5.49%
MLTX
Moon Lake Immunotherapeutics
CALL
$611,000
11.5K
Q4 2024
Reduced 5.86%
FULC
Fulcrum Therapeutics, Inc.
CALL
$609,000
130K
Q4 2024
Reduced 75.29%
RVPH
Reviva Pharmaceuticals Holdings, Inc.
CALL
$607,000
351K
Q3 2024
New holding
NUVB
Nuvation Bio Inc.
PUT
$593,000
223K
Q4 2024
Reduced 21.04%
AVXL
Anavex Life Sciences Corp.
PUT
$592,000
55.2K
Q4 2024
Added 843.8%
RYTM
Rhythm Pharmaceuticals, Inc.
PUT
$592,000
10.6K
Q4 2024
Reduced 60.67%
RCUS
Arcus Biosciences, Inc.
CALL
$585,000
39.3K
Q4 2024
Added 13.44%
XENE
Xenon Pharmaceuticals Inc.
CALL
$576,000
14.7K
Q4 2024
Reduced 54.7%
AKRO
Akero Therapeutics, Inc.
PUT
$575,000
20.7K
Q4 2024
Added 803.86%
TECH
Bio Techne Corp
PUT
$569,000
7.9K
Q4 2024
Added 45.96%
Filter Shares Options
Ken Griffin

Ken Griffin

Ken Griffin is the founder and CEO of Citadel Advisors, a successful investment firm that uses technology and data-driven approaches to investing. Griffin is known for his expertise in quantitative investing and his innovative approach to investing. He has generated strong returns for his clients over the long term.
Track Ken Griffin's portfolio
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email